Roivant Sciences Stock News

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Brian Cheng - JPMorgan Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.

Biopharmaceutical company Roivant Sciences (ROIV 0.18%) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million surpassed estimates of $5 million, reflecting the company's strategic momentum.

BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of cale...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sale...

Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics

BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a business update.

President Donald Trump's cabinet is often referred to as "The Avengers," with each member being accomplished in their field of expertise. Trump's cabinet has an overwhelming number of successful businessmen and businesswomen who were leaders in the business world prior to entering the government.

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Roivant, a global biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter, today announced a strategic partnership to advance rheumatology drug discovery and development by integrating Scipher's...